Fruquintinib monotherapy as third-line or later treatment for advanced pancreatic ductal adenocarcinoma: Updated results from a multicenter phase II study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #340P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • Monotherapy • P2 data • Oncology • Pancreatic Ductal Adenocarcinoma
|
|
Jieyun Zhang; Wang Qiong; Yusheng Wang; Guangliang Chen; Liu Yang; Yan Li; Weijian Guo
|